US antivirals giant Gilead Sciences today announced that it has signed non-exclusive, royalty-free voluntary licensing ...

Ferring Pharmaceuticals reported positive results from the OPTIMISE study, showing that a treat-to-target approach using ...

UK-based biotech LoQus23 Therapeutics has raised £35 million ($43 million) in a Series A financing round led by Forbion, with ...

Shattuck Labs is reducing its workforce by 40%, bringing its employee count below 50, and discontinuing its SL-172154 program ...

Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the ...

Aspen Neuroscience has opened a new facility near its San Diego headquarters to accelerate the production of induced ...

The US Food and Drug Administration (FDA) yesterday released its fiscal year 2023 (FY23) Generic Drug User Fee Amendments ...

Early Access Programs (EAPs) and Named Patient Programs (NPPs) provide a pathway for patients with life-threatening ...

Gritstone bio's stock dropped 62% after releasing interim Phase II data on its neoantigen immunotherapy, GRANITE, in ...

Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase ...

Santhera Pharmaceuticals’ rose as much as 5% to .46 francs yesterday after it announced the outcome of the LIONHEART study, confirming vamorolone’s distinctive action also a a mineralocorticoid ...

CAMP4 Therapeutics has announced a new research collaboration with BioMarin Pharmaceutical aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA (regRNA) ...